EA201391209A1 - Мостиковые производные пиперидина - Google Patents
Мостиковые производные пиперидинаInfo
- Publication number
- EA201391209A1 EA201391209A1 EA201391209A EA201391209A EA201391209A1 EA 201391209 A1 EA201391209 A1 EA 201391209A1 EA 201391209 A EA201391209 A EA 201391209A EA 201391209 A EA201391209 A EA 201391209A EA 201391209 A1 EA201391209 A1 EA 201391209A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- lower alkyl
- halogen
- substituted
- ring
- heteroatoms selected
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Настоящее изобретение относится к соединениям формулыгде гетарил I представляет собой пяти- или шестичленную гетероарильную группу, содержащую 1-3 гетероатома, выбранных из S или N; гетарил II представляет собой шестичленную гетероарильную группу, содержащую 1-3 гетероатома, выбранных из S или N, или представляет собой двухкольцевую систему, содержащую 1-4 гетероатома, выбранных из S или N, где по меньшей мере одно кольцо является ароматическим; Rпредставляет собой низший алкил, низший алкокси, низший алкил, замещенный галогеном, или галоген; Rпредставляет собой низший алкил, низший алкил, замещенный галогеном, водород, низший алкокси, циклоалкил, замещенный низшим алкилом, или низший алкил, замещенный галогеном, или представляет собой низший алкил, замещенный гидрокси, или представляет собой фурил, или представляет собой О-бензил, -(СН)-фенил, возможно замещенный галогеном, низший алкокси, низший алкил, замещенный галогеном, низшим алкилом или циано; Rпредставляет собой водород или низший алкил; Y представляет собой-(СН)-, -СНОСН-, -СНО-, CHS-, -CHSCH- и присоединен к двум кольцевым атомам углерода, связь осуществляется через каждый кольцевой атом углерода а и b или через каждый кольцевой атом c и d; р представляет собой 0 или 1; m представляет собой 0, 1 или 2; если m представляет собой 2, тогда Rмогут быть одинаковыми или различными; n представляет собой 2 или 3; o представляет собой 0, 1 или 2, если о представляет собой 2, тогда Rмогут быть одинаковыми или различными; или их фармацевтически активным кислотно-аддитивным солям. Настоящие соединения формулы I являются модуляторами амилоида бета и, таким образом, они могут быть полезны для лечения или профилактики заболеваний, ассоциированных с отложением
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11156587 | 2011-03-02 | ||
| PCT/EP2012/053301 WO2012116965A1 (en) | 2011-03-02 | 2012-02-28 | Bridged piperidine derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201391209A1 true EA201391209A1 (ru) | 2013-12-30 |
| EA025035B1 EA025035B1 (ru) | 2016-11-30 |
Family
ID=45757448
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201391209A EA025035B1 (ru) | 2011-03-02 | 2012-02-28 | Мостиковые производные пиперидина |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US8703763B2 (ru) |
| EP (1) | EP2681214B1 (ru) |
| JP (1) | JP5753591B2 (ru) |
| KR (1) | KR101550122B1 (ru) |
| CN (1) | CN103403003B (ru) |
| BR (1) | BR112013021924A2 (ru) |
| CA (1) | CA2824239A1 (ru) |
| CL (1) | CL2013002474A1 (ru) |
| CO (1) | CO6761320A2 (ru) |
| CR (1) | CR20130358A (ru) |
| EA (1) | EA025035B1 (ru) |
| EC (1) | ECSP13012858A (ru) |
| IL (1) | IL227251A (ru) |
| MA (1) | MA34964B1 (ru) |
| MX (1) | MX2013009031A (ru) |
| MY (1) | MY167264A (ru) |
| PE (1) | PE20140250A1 (ru) |
| SG (1) | SG193239A1 (ru) |
| UA (1) | UA110368C2 (ru) |
| WO (1) | WO2012116965A1 (ru) |
| ZA (1) | ZA201305322B (ru) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2147948B1 (en) * | 2007-04-25 | 2014-11-12 | Nissan Chemical Industries, Ltd. | Polyimide precursor, polyimide, and coating solution for under layer film for image formation |
| US11090297B2 (en) | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
| WO2017042114A1 (en) * | 2015-09-09 | 2017-03-16 | F. Hoffmann-La Roche Ag | Bridged piperidine derivatives |
| MX2018005890A (es) | 2015-11-12 | 2018-08-15 | Hoffmann La Roche | Composiciones para tratar atrofia muscular espinal. |
| IL281633B (en) | 2015-12-10 | 2022-07-01 | Ptc Therapeutics Inc | Methods for treating Huntington's disease |
| JP6872550B2 (ja) * | 2015-12-10 | 2021-05-19 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 架橋されたピペリジン誘導体 |
| WO2018001918A1 (en) | 2016-06-27 | 2018-01-04 | F. Hoffmann-La Roche Ag | Triazolopyridines as gamma-secretase modulators |
| EP3484884B1 (en) | 2016-07-14 | 2021-01-27 | Hoffmann-La Roche AG | Fused pyrimidine derivatives |
| CA3035092C (en) | 2016-08-24 | 2022-05-31 | Prilenia Therapeutics Development Ltd. | Use of pridopidine for treating functional decline |
| AR109829A1 (es) * | 2016-09-29 | 2019-01-30 | Hoffmann La Roche | Derivados de piperidina puenteados |
| EP3523304B1 (en) * | 2016-10-04 | 2021-01-27 | H. Hoffnabb-La Roche Ag | Bicyclic heteroaryl derivatives |
| AR110001A1 (es) * | 2016-11-01 | 2019-02-13 | Hoffmann La Roche | Derivados heteroarilo bicíclicos |
| WO2018087018A1 (en) | 2016-11-08 | 2018-05-17 | F. Hoffmann-La Roche Ag | Phenoxytriazoles |
| EP3554502A4 (en) | 2016-12-16 | 2021-01-06 | Pipeline Therapeutics, Inc. | METHOD FOR TREATMENT OF COCHLEA SYNAPTOPATHY |
| SG11201911615WA (en) | 2017-06-05 | 2020-01-30 | Ptc Therapeutics Inc | Compounds for treating huntington's disease |
| US11382918B2 (en) | 2017-06-28 | 2022-07-12 | Ptc Therapeutics, Inc. | Methods for treating Huntington's Disease |
| US11395822B2 (en) | 2017-06-28 | 2022-07-26 | Ptc Therapeutics, Inc. | Methods for treating Huntington's disease |
| WO2019121596A1 (en) * | 2017-12-19 | 2019-06-27 | Boehringer Ingelheim International Gmbh | Triazolo pyridines as modulators of gamma-secretase |
| JP7335248B2 (ja) * | 2018-01-22 | 2023-08-29 | エフ． ホフマン－ラ ロシュ アーゲー | トリアゾロ－アゼピン誘導体 |
| BR112020019373A2 (pt) | 2018-03-27 | 2020-12-29 | Ptc Therapeutics, Inc. | Compostos para o tratamento da doença de hutington |
| EA202092896A1 (ru) | 2018-06-27 | 2021-04-13 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Гетероциклические и гетероарильные соединения для лечения болезни гентингтона |
| WO2020005882A1 (en) | 2018-06-27 | 2020-01-02 | Ptc Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
| PL3846903T3 (pl) * | 2018-09-03 | 2024-05-06 | F. Hoffmann-La Roche Ag | Bicykliczne pochodne heteroarylowe |
| KR20210102900A (ko) * | 2018-12-13 | 2021-08-20 | 에프. 호프만-라 로슈 아게 | 알츠하이머 병의 치료를 위한 감마-세크레타제 조절제로서 7-페녹시-N-(3-아자바이사이클로[3.2.1]옥탄-8-일)-6,7-다이하이드로-5H-피롤로[1,2-b][1,2,4]트라이아졸-2-아민 유도체 및 관련 화합물 |
| CN113372364B (zh) * | 2020-03-10 | 2024-05-31 | 明慧医药（上海）有限公司 | 一类jak激酶抑制剂及其制备和应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6432985B2 (en) | 2000-04-25 | 2002-08-13 | Hoffmann-La Roche Inc. | Neuroprotective substituted piperidine compounds with activity as NMDA NR2B subtype selective antagonists |
| US7037902B2 (en) | 2002-07-03 | 2006-05-02 | Receptron, Inc. | Affinity small molecules for the EPO receptor |
| HU227684B1 (en) | 2003-08-29 | 2011-11-28 | Sanofi Aventis | Adamantane and azabicyclo-octane and nonane derivatives and their use as dpp-iv inhibitors |
| BRPI0616667B1 (pt) * | 2005-10-06 | 2017-07-18 | Nippon Soda Co. , Ltd. | Compounds of cyclical amine or salts thereof or non-oxides thereof, and agents for control of fever |
| AU2009216851B2 (en) | 2008-02-22 | 2013-11-07 | F. Hoffmann-La Roche Ag | Modulators for amyloid beta |
| US20110190269A1 (en) | 2010-02-01 | 2011-08-04 | Karlheinz Baumann | Gamma secretase modulators |
| US8486967B2 (en) | 2010-02-17 | 2013-07-16 | Hoffmann-La Roche Inc. | Heteroaryl substituted piperidines |
-
2012
- 2012-02-27 US US13/405,404 patent/US8703763B2/en not_active Expired - Fee Related
- 2012-02-28 PE PE2013002000A patent/PE20140250A1/es not_active Application Discontinuation
- 2012-02-28 CA CA2824239A patent/CA2824239A1/en not_active Abandoned
- 2012-02-28 BR BR112013021924-6A patent/BR112013021924A2/pt not_active IP Right Cessation
- 2012-02-28 MA MA36238A patent/MA34964B1/fr unknown
- 2012-02-28 KR KR1020137025946A patent/KR101550122B1/ko not_active IP Right Cessation
- 2012-02-28 JP JP2013555846A patent/JP5753591B2/ja not_active Expired - Fee Related
- 2012-02-28 MX MX2013009031A patent/MX2013009031A/es active IP Right Grant
- 2012-02-28 EA EA201391209A patent/EA025035B1/ru not_active IP Right Cessation
- 2012-02-28 SG SG2013065107A patent/SG193239A1/en unknown
- 2012-02-28 CN CN201280011284.3A patent/CN103403003B/zh not_active Expired - Fee Related
- 2012-02-28 WO PCT/EP2012/053301 patent/WO2012116965A1/en active Application Filing
- 2012-02-28 MY MYPI2013003198A patent/MY167264A/en unknown
- 2012-02-28 UA UAA201311595A patent/UA110368C2/uk unknown
- 2012-02-28 EP EP12705884.0A patent/EP2681214B1/en not_active Not-in-force
-
2013
- 2013-06-27 IL IL227251A patent/IL227251A/en active IP Right Grant
- 2013-07-15 ZA ZA2013/05322A patent/ZA201305322B/en unknown
- 2013-07-23 CR CR20130358A patent/CR20130358A/es unknown
- 2013-07-25 CO CO13176486A patent/CO6761320A2/es unknown
- 2013-08-28 CL CL2013002474A patent/CL2013002474A1/es unknown
- 2013-08-30 EC ECSP13012858 patent/ECSP13012858A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CR20130358A (es) | 2013-10-03 |
| KR101550122B1 (ko) | 2015-09-03 |
| KR20130140142A (ko) | 2013-12-23 |
| PE20140250A1 (es) | 2014-03-12 |
| ECSP13012858A (es) | 2013-10-31 |
| CN103403003A (zh) | 2013-11-20 |
| MY167264A (en) | 2018-08-14 |
| MA34964B1 (fr) | 2014-03-01 |
| CL2013002474A1 (es) | 2014-05-30 |
| CO6761320A2 (es) | 2013-09-30 |
| EP2681214A1 (en) | 2014-01-08 |
| CN103403003B (zh) | 2016-09-14 |
| EA025035B1 (ru) | 2016-11-30 |
| JP2014506903A (ja) | 2014-03-20 |
| CA2824239A1 (en) | 2012-09-07 |
| ZA201305322B (en) | 2014-04-30 |
| US20120225884A1 (en) | 2012-09-06 |
| IL227251A (en) | 2016-09-29 |
| MX2013009031A (es) | 2013-09-02 |
| NZ612525A (en) | 2015-08-28 |
| UA110368C2 (en) | 2015-12-25 |
| AU2012222426A1 (en) | 2013-07-11 |
| BR112013021924A2 (pt) | 2020-10-20 |
| JP5753591B2 (ja) | 2015-07-22 |
| US8703763B2 (en) | 2014-04-22 |
| IL227251A0 (en) | 2013-09-30 |
| WO2012116965A1 (en) | 2012-09-07 |
| EP2681214B1 (en) | 2017-03-22 |
| SG193239A1 (en) | 2013-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201391209A1 (ru) | Мостиковые производные пиперидина | |
| CY1117976T1 (el) | Παραγωγα πιπεριδινης | |
| AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
| HK1165954A1 (en) | Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors | |
| JP2013509392A5 (ru) | ||
| RU2014129742A (ru) | Производные бензолсульфонамида в качестве модуляторов rorc | |
| EA201291409A1 (ru) | Производные индолизина, способ их получения и их терапевтическое применение | |
| EA201690019A1 (ru) | Производное аминотриазина и содержащая его фармацевтическая композиция | |
| AR089019A1 (es) | Derivados modificados de 4-fenil-piridina | |
| EA201171004A1 (ru) | Пиридазиноновые соединения | |
| NO20090564L (no) | Modulatorer av glukokortikoid reseptor, AP-1 og/eller NF-KB aktivitet og anvendelse derav | |
| AR087915A1 (es) | N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1 | |
| CY1114689T1 (el) | C7-φθορο υποκατεστημενες ενωσεις τετρακυκλινης | |
| EA201370184A1 (ru) | Гетероарильные производные | |
| NO20091681L (no) | Modulatorer av glukortikoidreseptoren, AP-1, og/eller NF-kappaB aktivitet og anvendelse derav | |
| EA201490754A1 (ru) | Производные карбамата/мочевины, содержащие пиперидиновые и пиперазиновые кольца, в качестве ингибиторов н3 рецептора | |
| AR093408A1 (es) | Derivados de oxazolidin-2-ona-pirimidina | |
| MX2014004144A (es) | Derivados de etinilo como moduladores alostericos del receptor de glutamato metabotropico del subtipo 5 (mglur5). | |
| RU2016111811A (ru) | ПРОИЗВОДНЫЕ КЕТО-ИМИДАЗОПИРИДИНА В КАЧЕСТВЕ МОДУЛЯТОРОВ RORc | |
| BR112014004275A2 (pt) | derivados de isoxazolina como compostos inseticidas | |
| ECSP11011196A (es) | Derivados de piperidina | |
| JP2016512541A5 (ru) | ||
| AR071619A1 (es) | Compuestos de pirazina fusionados utiles para el tratamiento de enfermedades degenerativas e inflamatorias y composiciones farmaceuticas que los contienen. | |
| WO2012131656A3 (en) | Compounds for use as therapeutic agents affecting p53 expression and/or activity | |
| EA201270610A1 (ru) | Хинуклидиновые соединения как альфа-7 лиганды ацетилхолинового рецептора |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM |
|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): RU |